This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sher, Y.-P. Articles by Peck, K. Search for Related Content PubMed PubMed Citation Articles by Sher, Y.-P. Articles by Peck, K.

Human Kallikrein 8 Protease Confers a Favorable Clinical Outcome in Non–Small Cell Lung Cancer by Suppressing Tumor Cell Invasiveness

Institutes of ¹ Biomedical Sciences and ² Statistical Science, Academia Sinica; ³ Institute of Molecular Medicine and ⁴ Center for Genomic Medicine, National Taiwan University; ⁵ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; and ⁶ National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan, Republic of China

Requests for reprints: Konan Peck, Institute of Biomedical Sciences, Academia Sinica, 128, Sec. 2, Academia Road, Taipei, Taiwan 115, Republic of China. Phone: 886-2-2652-3072; Fax: 886-2-2785-8594; E-mail: konan{at}ibms.sinica.edu.tw.

The human kallikrein 8 (KLK8) gene, a member of the human tissue kallikrein gene family, encodes a serine protease. The KLK8 protein (hK8) is known to be a favorable prognostic marker in ovarian cancer, but the biological basis of this is not understood. We found that overexpressing the KLK8 gene in highly invasive lung cancer cell lines suppresses their invasiveness. This role in invasiveness was further confirmed by the fact that inhibition of endogenous KLK8 expression with a specific short hairpin RNA reduced cancer cell invasiveness. In situ degradation and cell adhesion assays showed that proteins produced from KLK8 splice variants modify the extracellular microenvironment by cleaving fibronectin. DNA microarray experiments and staining of cells for actin filaments revealed that the degradation of fibronectin by hK8 suppresses integrin signaling and retards cancer cell motility by inhibiting actin polymerization. In addition, studies in a mouse model coupled with the detection of circulating tumor cells by quantitative PCR for the human Alu sequence showed that KLK8 suppresses tumor growth and invasion in vivo. Finally, studies of clinical specimens from patients with non–small cell lung cancer showed that the time to postoperative recurrence was longer for early-stage patients (stages I and II) with high KLK8 expression (mean, 49.9 months) than for patients with low KLK8 expression (mean, 22.9 months). Collectively, these findings show that KLK8 expression confers a favorable clinical outcome in non–small cell lung cancer by suppressing tumor cell invasiveness. (Cancer Res 2006; 66(24): 11763-70)

This article has been cited by other articles:

				C. Planque, L. Li, Y. Zheng, A. Soosaipillai, K. Reckamp, D. Chia, E. P. Diamandis, and L. Goodglick A Multiparametric Serum Kallikrein Panel for Diagnosis of Non-Small Cell Lung Carcinoma Clin. Cancer Res., March 1, 2008; 14(5): 1355 - 1362. [Abstract] [Full Text] [PDF]